Literature DB >> 21987061

Cardiac ion channels and mechanisms for protection against atrial fibrillation.

Morten Grunnet1, Bo Hjorth Bentzen, Ulrik Svane Sørensen, Jonas Goldin Diness.   

Abstract

Atrial fibrillation (AF) is recognised as the most common sustained cardiac arrhythmia in clinical practice. Ongoing drug development is aiming at obtaining atrial specific effects in order to prevent pro-arrhythmic, devastating ventricular effects. In principle, this is possible due to a different ion channel composition in the atria and ventricles. The present text will review the aetiology of arrhythmias with focus on AF and include a description of cardiac ion channels. Channels that constitute potentially atria-selective targets will be described in details. Specific focus is addressed to the recent discovery that Ca(2+)-activated small conductance K(+) channels (SK channels) are important for the repolarisation of atrial action potentials. Finally, an overview of current pharmacological treatment of AF is included.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21987061     DOI: 10.1007/112_2011_3

Source DB:  PubMed          Journal:  Rev Physiol Biochem Pharmacol        ISSN: 0303-4240            Impact factor:   5.545


  11 in total

1.  Pharmacological blockade of small conductance Ca2+-activated K+ channels by ICA reduces arrhythmic load in rats with acute myocardial infarction.

Authors:  Laura A Hundahl; Stefan M Sattler; Lasse Skibsbye; Jonas G Diness; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Pflugers Arch       Date:  2017-03-11       Impact factor: 3.657

2.  Sarcoplasmic reticulum Ca²⁺ release is both necessary and sufficient for SK channel activation in ventricular myocytes.

Authors:  Dmitry Terentyev; Jennifer A Rochira; Radmila Terentyeva; Karim Roder; Gideon Koren; Weiyan Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-12-31       Impact factor: 4.733

Review 3.  Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.

Authors:  Heike Wulff; Ralf Köhler
Journal:  J Cardiovasc Pharmacol       Date:  2013-02       Impact factor: 3.105

Review 4.  Role of ion channels in heart failure and channelopathies.

Authors:  Ann-Kathrin Rahm; Patrick Lugenbiel; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Biophys Rev       Date:  2018-07-17

5.  The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Victoria M Robinson; Morten Grunnet; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2020-08       Impact factor: 3.271

6.  Expression changes of ionic channels in early phase of cultured rat atrial myocytes induced by rapid pacing.

Authors:  Qiang Ji; Hua Liu; Yunqing Mei; Xisheng Wang; Jing Feng; Wenjun Ding
Journal:  J Cardiothorac Surg       Date:  2013-09-29       Impact factor: 1.637

7.  Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs.

Authors:  Zhiqiang Zhao; Weimin Li; Xinghua Wang; Yan Chen; Jian Li; Wansong Yang; Lijun Cheng; Enzhao Liu; Tong Liu; Guangping Li
Journal:  Anatol J Cardiol       Date:  2014-11-11       Impact factor: 1.596

8.  The Venom of Ornithoctonus huwena affect the electrophysiological stability of neonatal rat ventricular myocytes by inhibiting sodium, potassium and calcium current.

Authors:  Sha Yan; Pengfei Huang; Ying Wang; Xiongzhi Zeng; Yiya Zhang
Journal:  Channels (Austin)       Date:  2018-01-01       Impact factor: 2.581

Review 9.  Immune remodeling and atrial fibrillation.

Authors:  Yajun Yao; Mei Yang; Dishiwen Liu; Qingyan Zhao
Journal:  Front Physiol       Date:  2022-07-22       Impact factor: 4.755

10.  A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics.

Authors:  Radda Rusinova; Roger E Koeppe; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2015-11-16       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.